Cite
HARVARD Citation
Kaufman, H. et al. (n.d.). Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial. Journal for immunotherapy of cancer. p. . [Online].